Batlevi CL et al. A phase 1b/3 randomized, double-blind, 3-stage study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. ASH 2020;Abstract 2052.

Delfau-Larue MH et al. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Adv 2020;4(14):3217-23. Abstract

Fowler NH et al. Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: Interim analysis of the phase 2 Elara trial. ASH 2020;Abstract 1149.

Herrera AF et al. Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma. ASH 2020;Abstract 472.

Jacobson CA et al. Primary analysis of Zuma-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2020;Abstract 700.

Maddocks KJ et al. Long-term subgroup analyses from L-Mind, a phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. ASH 2020;Abstract 3021.

Maloney DG et al. Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) vs axicabtagene ciloleucel (axi-cel) and tisagenlecleucel in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). ASH 2020;Abstract 2116.

Roemer MGM et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016;34(23):2690-7. Abstract

Salles G et al. Analyzing efficacy outcomes from the phase 2 study of single-agent tazemetostat as third-line therapy in patients with relapsed or refractory follicular lymphoma to identify predictors of response. ASH 2020;Abstract 2047.

Straus DJ et al. Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study. ASH 2020;Abstract 2973.

Villasboas JC, Ansell SA. Checkpoint inhibition: Programmed cell death 1 and programmed cell death 1 ligand inhibitors in Hodgkin lymphoma. Cancer J 2016;22(1):17-22. Abstract

Wang M et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382(14):1331-42. Abstract